Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$14.31 -1.1%	$11.04	$6.36 ▼ $47.45	$1.63B	1.17	1.67 million shs	669,483 shs
EWTX Edgewise Therapeutics	$15.40 -0.2%	$14.34	$10.60 ▼ $38.12	$1.61B	0.28	1.20 million shs	241,747 shs
NKTR Nektar Therapeutics	$8.27 -5.6%	$9.97	$6.48 ▼ $22.79	$1.55B	0.55	134,180 shs	118,696 shs
SVRA Savara	$2.24 -1.1%	$2.83	$1.89 ▼ $5.11	$386.29M	0.32	1.42 million shs	50,952 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	-0.75%	+3.36%	+19.50%	+20.00%	-56.20%
EWTX Edgewise Therapeutics	-2.10%	+4.05%	+3.56%	-39.93%	-13.76%
NKTR Nektar Therapeutics	-8.27%	-13.46%	-17.75%	-34.88%	-54.73%
SVRA Savara	+2.73%	-5.04%	-23.91%	-13.41%	-44.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYN Dyne Therapeutics	2.7064 of 5 stars	4.5	0.0	0.0	2.2	3.3	0.0
EWTX Edgewise Therapeutics	2.7289 of 5 stars	4.4	1.0	0.0	1.6	3.3	0.0
NKTR Nektar Therapeutics	4.2396 of 5 stars	3.5	4.0	4.2	2.2	2.5	0.0
SVRA Savara	2.2429 of 5 stars	3.3	1.0	0.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYN Dyne Therapeutics	3.00	Buy	$44.93	214.08% Upside
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$39.78	158.38% Upside
NKTR Nektar Therapeutics	3.00	Buy	$67.50	716.20% Upside
SVRA Savara	2.67	Moderate Buy	$7.17	220.66% Upside

Current Analyst Ratings Breakdown

Latest SVRA, DYN, NKTR, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	DYN Dyne Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00
5/29/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$46.00
5/29/2025	SVRA Savara	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$6.00 ➝ $2.00
5/28/2025	SVRA Savara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$3.00 ➝ $2.00
5/28/2025	SVRA Savara	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $8.00
5/28/2025	SVRA Savara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$8.00 ➝ $7.00
5/12/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/9/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $38.00
5/9/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
NKTR Nektar Therapeutics	$87.25M	17.64	N/A	N/A	$0.69 per share	11.99
SVRA Savara	N/A	N/A	N/A	N/A	$1.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYN Dyne Therapeutics	-$235.94M	-$3.59	N/A	N/A	N/A	N/A	-57.46%	-51.62%	8/11/2025 (Estimated)
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	8/6/2025 (Estimated)
NKTR Nektar Therapeutics	-$276.06M	-$0.64	N/A	N/A	N/A	-180.70%	-173.28%	-46.31%	8/6/2025 (Estimated)
SVRA Savara	-$54.70M	-$0.48	N/A	N/A	N/A	N/A	-58.89%	-46.44%	8/11/2025 (Estimated)

Latest SVRA, DYN, NKTR, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	SVRA Savara	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million
3/27/2025	Q4 2024	SVRA Savara	-$0.11	-$0.13	-$0.02	-$0.13	N/A	$0.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYN Dyne Therapeutics	N/A	17.02	17.02
EWTX Edgewise Therapeutics	N/A	26.35	26.35
NKTR Nektar Therapeutics	N/A	4.24	4.24
SVRA Savara	0.13	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYN Dyne Therapeutics	96.68%
EWTX Edgewise Therapeutics	N/A
NKTR Nektar Therapeutics	75.88%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
DYN Dyne Therapeutics	14.14%
EWTX Edgewise Therapeutics	23.20%
NKTR Nektar Therapeutics	5.25%
SVRA Savara	5.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYN Dyne Therapeutics	100	113.67 million	80.63 million	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	71.86 million	Optionable
NKTR Nektar Therapeutics	220	186.10 million	177.62 million	Optionable
SVRA Savara	N/A	172.84 million	162.82 million	Optionable

SVRA, DYN, NKTR, and EWTX Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 13 at 10:15 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 12 at 9:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 11 at 9:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 9, 2025 | accessnewswire.com

savara elects board members and approves proposals at annual meeting

June 8, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 7, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 6, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 5, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 4, 2025 | accessnewswire.com

Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA)

June 4, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 3, 2025 | accessnewswire.com

Joseph S. Mccracken Acquires 10,000 Shares of Savara Inc (NASDAQ:SVRA) Stock

June 3, 2025 | insidertrades.com

HC Wainwright Has Negative Outlook of Savara FY2026 Earnings

June 3, 2025 | americanbankingnews.com

Savara assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA

June 2, 2025 | globenewswire.com

Savara Inc (NASDAQ:SVRA) Director Joseph S. Mccracken Acquires 10,000 Shares

June 2, 2025 | marketbeat.com

Wellington Management Group LLP Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA)

June 2, 2025 | marketbeat.com

What is HC Wainwright's Forecast for Savara FY2026 Earnings?

June 2, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 1, 2025 | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

June 1, 2025 | prnewswire.com

Two Sigma Investments LP Boosts Stake in Savara Inc (NASDAQ:SVRA)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
After Earnings Beats, These 3 Stocks Are on Analysts’ Radars
By Leo Miller | May 20, 2025
View After Earnings Beats, These 3 Stocks Are on Analysts’ Radars
Joby's Saudi MoU: Strong Initial Reaction Meets Market Dynamics
By Jeffrey Neal Johnson | June 4, 2025
View Joby's Saudi MoU: Strong Initial Reaction Meets Market Dynamics
Steel Dynamics Shares Climb After Tariff Announcement
By Dan Schmidt | June 3, 2025
View Steel Dynamics Shares Climb After Tariff Announcement

SVRA, DYN, NKTR, and EWTX Company Descriptions

Dyne Therapeutics NASDAQ:DYN

$14.30 -0.16 (-1.07%)

As of 11:17 AM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Edgewise Therapeutics NASDAQ:EWTX

$15.40 -0.03 (-0.16%)

As of 11:17 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Nektar Therapeutics NASDAQ:NKTR

$8.27 -0.49 (-5.59%)

As of 11:18 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Savara NASDAQ:SVRA

$2.24 -0.03 (-1.11%)

As of 11:17 AM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time